Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Myocardial perfusion imaging associated with 31% cost reduction -- clinical study.

This article was originally published in The Gray Sheet

Executive Summary

MYOCARDIAL PERFUSION IMAGING ASSOCIATED WITH 31% COST SAVINGS according to results from the Economics of Noninvasive Diagnosis (END) study, presented Nov. 13 at the American Heart Association scientific sessions in New Orleans. Average three-year per-patient medical costs for patients who underwent stress MPI imaging prior to referral for catheterization (n=5,823) was $3,470, $1,571 lower than the average three-year $5,041 per-patient cost for patients who did not receive the cardiac blood flow screening technique (n=5,423).

Latest Headlines
See All
UsernamePublicRestriction

Register

MT007160

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel